CTLA4 and rheumatic disorder: CTLA-4 is a co-inhibitory surface molecule that is constitutively expressed in Treg and its expression assay is of great interest for the diagnosis and clinical management of both PIRDs (75–78) and autoimmune diseases (rheumatic diseases) (79).